Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer.
- Author:
Na HAN
1
;
Zong-wen LIU
;
Jian WANG
;
Zhong-mian ZHANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Camptothecin; administration & dosage; adverse effects; analogs & derivatives; Carcinoma, Non-Small-Cell Lung; drug therapy; Cisplatin; administration & dosage; adverse effects; Female; Humans; Lung Neoplasms; drug therapy; Male; Middle Aged
- From: Journal of Southern Medical University 2010;30(2):349-350
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and adverse effects of irinotecan combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).
METHODSFifteen patients (10 males and 5 females) aged from 32 to 58 years (median age of 47 years) with KPS>70 and the diagnosis of advanced NSCLC by pathology or cytology were treated with cisplatin 80 mg/m(2) plus irinotecan 60 mg/m(2) by intravenous infusion on 1, 8, 15 days, and the treatment was repeated every 4 weeks. After treatment for at least 2 cycles, the therapeutic effects and adverse drug reactions were evaluated.
RESULTSOf all the cases, PR was achieved in 4 (26.7%), SD in 9 (60%), and PD in 2 (13.3%), with an overall response rate of 26.7%. The median survival time was 11 months and 1-year survival rate was 46.7% (7/15). The main toxicities were delayed diarrhea and granulocytopenia.
CONCLUSIONIrinotecan plus cisplatin is an effective and tolerable treatment for advanced NSCLC with low incidence of adverse effects.
